Business Context and Reporting Period
Cytosorbents Corporation (formerly Medasorb Technologies Corporation) filed this Form 8-K on May 5, 2010, to report the entry into a material definitive agreement. The company is a Nevada corporation focused on the development and commercialization of CytoSorb, a medical device.
Key Financial Metrics and Transaction Details
This filing reports a financing arrangement rather than operational financial results. Key metrics include:
- Agreement Value: Up to $6 million in potential common stock purchases over a 25-month period.
- Investor: Lincoln Park Capital Fund, LLC (LPC).
- Commitment Fee: 1,153,846 shares of common stock issued immediately to LPC.
- Future Issuance: An equivalent amount of shares (1,153,846) to be issued pro rata as LPC purchases the $6 million.
- Purchase Price: Based on prevailing market prices at the time of sale with no fixed discount.
- Price Floor: LPC has no obligation to purchase shares if the market price is below $0.10.
- Transaction Range: Sales to LPC will occur in amounts between $50,000 and $750,000 per transaction, subject to conditions.
The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes
The primary material change is the establishment of a flexible equity financing mechanism. Unlike traditional fixed-price offerings, this agreement allows the company to control the timing and amount of share sales while ensuring a potential capital source of up to $6 million. The company retains the right to terminate the agreement at any time without cost.
Guidance, Outlook, and Use of Proceeds
Management intends to use the proceeds from this agreement for the following purposes:
- Completion of the European Sepsis Trial.
- Pursuit of CE Mark approval.
- Commercialization of CytoSorb.
- Expansion of the product pipeline.
- General working capital.
The agreement contains no negative covenants, restrictions on future funding, penalties, or liquidated damages.
Investor Verification Checklist
- Verify the current market price of Cytosorbents common stock to assess the price floor constraint ($0.10).
- Review the full text of the Purchase Agreement (Exhibit 10.1) for specific conditions governing the $50,000 to $750,000 sales limits.
- Confirm the status of the European Sepsis Trial and CE Mark approval timeline.
- Monitor the company's ability to issue the pro rata shares as LPC exercises its purchase rights.
- Check for any subsequent filings regarding the effectiveness of the registration statement required by the Registration Rights Agreement.